MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T. Goh, Vikas Gupta, Claire Harrison, Jean Jacques Kiladjian, Mihaela C. Lazaroiu, Adam Mead, Donal McLornan, Mary F. McMullin, Stephen T. Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung Soo Yoon, Mark M. Kowalski*Ruben A. Mesa

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

32 引文 斯高帕斯(Scopus)

摘要

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

原文英語
頁(從 - 到)1449-1458
頁數10
期刊Future Oncology
17
發行號12
DOIs
出版狀態已出版 - 04 2021
對外發佈

文獻附註

Publisher Copyright:
© 2021 Future Oncology. All rights reserved.

指紋

深入研究「MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic」主題。共同形成了獨特的指紋。

引用此